Innovative Life Sciences Company Boosts Immune Function in Livestock Without the Use of Antibiotics
Source: Streetwise Reports  (6/2/21)
Avivagen's OxC-betaâ„¢ Livestock products could play a pivotal role in the global mandate to remove all in-feed antibiotics as growth promoters. More >

Biotech Receives National Cancer Institute Resources Award for Ovarian Cancer Vaccine Program
Source: Streetwise Reports  (6/2/21)
The award and other recent developments at Anixa Biosciences are covered in an H.C. Wainwright & Co. report. More >

Biotech Firm Confirms 100% Accuracy of COVID-19 Mutation Assays
Source: Streetwise Reports  (6/2/21)
Applied DNA Sciences' SARS-CoV-2 mutation panel and its validation are discussed in a ROTH Capital Partners report. More >

Constellation Pharma Shares Sparkle on $1.7 Billion Buyout Offer
Source: Streetwise Reports  (6/2/21)
Shares of Constellation Pharmaceuticals Inc. traded 65% higher after the company reported it entered into an agreement to be acquired by MorphoSys AG in an all-cash transaction for $34 per share. More >

Analyst: Clinical News, Catalysts Portend 'Rich' Q2/21 for Biopharma
Source: Streetwise Reports  (5/26/21)
Second-quarter clinical events related to Anavex Life Sciences' pipeline are summarized in a Dawson James Securities report. More >

Analyst: New Data Show Cancer Therapeutic 'Continues to Deliver Benefit'
Source: Streetwise Reports  (5/26/21)
Data from two of Oncternal Therapeutics' clinical trials in oncological indications are discussed in an H.C. Wainwright & Co. report. More >

Verastem Shares Rise 25% as FDA Issues Breakthrough Therapy Designation for Ovarian Cancer Drug
Source: Streetwise Reports  (5/24/21)
Verastem Inc. shares reached a new 52-week high after the company reported its VS-6766 in combination with defactinib was granted breakthrough therapy designation by the FDA for treatment of recurrent low-grade serous ovarian cancer. More >

Biopharma Has 'Trials Progressing; Multiple 2022 Data Readouts' Including for PTSD
Source: Streetwise Reports  (5/19/21)
Updates on Aptinyx's three central nervous system drug candidates and the company's Q1/21 earnings are delivered in an H.C. Wainwright & Co. report. More >

Analyst Highlights Two Key Catalysts for Biotech
Source: Streetwise Reports  (5/19/21)
The biopharma aTyr's upcoming drug application and clinical-trial results are discussed in a ROTH Capital Partners report. More >

Sarepta Therapeutics Posts Positive Results in Duchenne Muscular Dystrophy Study
Source: Streetwise Reports  (5/18/21)
Sarepta Therapeutics shares traded 8% higher after the company reported its investigational gene therapy SRP-9001, used for treating Duchenne's Muscular Dystrophy, had "positive 12-week expression and safety results." More >

Apellis Gains FDA Approval for Empaveli to Treat Chronic Blood Disorder
Source: Streetwise Reports  (5/17/21)
Shares of Apellis Pharmaceuticals Inc. traded 20% higher after the company reported it received U.S. FDA approval for EMPAVELI (pegcetacoplan) for use in treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare, chronic life-threatening blood disorder. More >

Analyst: Biotech Expecting a 'Catalyst-Rich' Second Half of the Year
Source: Streetwise Reports  (5/13/21)
An H.C. Wainwright & Co. report discusses Gritstone Bio's recent earnings and significant corporate events as the firm plans to release data on cancer and COVID-19 vaccines later this year.
More >

Pharma Developer Finds Ifenprodil Reduces Interleukin 6 in Phase 2b/3 COVID Trial
Source: Streetwise Reports  (5/13/21)
Algernon Pharmaceuticals reported that Ifenprodil was shown to reduce interleukin 6 in its Phase 2b/3 COVID-19 Study, which the company states may have positive implications for its use in its ongoing Phase 2 trial of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough. More >

Multiplan Shares Rise on Strong YoY Gain in Q1 Net Income and Forward Outlook
Source: Streetwise Reports  (5/13/21)
Multiplan Corp. shares traded 17% higher after the company reported Q1/21 net income of $45.9 million, compared to a net loss of $2.6 million in the corresponding quarter last year. More >

Life Sciences Firm Is at 'an Inflection Point with Significant Sales Increases Just around the Corner'
Source: Streetwise Reports  (5/12/21)
Noble Capital Markets noted in a research report that shortly after receiving its largest single order to date, a 4.4-ton order for OxC-beta Livestock, Avivagen Inc. has received a new order for 4 tons per month from its representative in Mexico. More >

Second Sight Shares Shine Brightly After Firm Posts Orion Study Results
Source: Streetwise Reports  (5/12/21)
Second Sight Medical Products Inc. shares traded 25% higher after the company reported the results from a two-year study of its Orion Visual Cortical Prosthesis System. More >

AbbVie's Allergan Aesthetics to Acquire Soliton for $550 Million
Source: Streetwise Reports  (5/10/21)
Soliton Inc. shares traded 25% higher after the company reported it had agreed to be acquired by AbbVie Inc.'s Allergan Aesthetics for $22.60 per share in an all cash transaction. More >

Telehealth's Transformation of Healthcare Will Outlive the Pandemic, Boost AI Applications
Source: McAlinden Research for Streetwise Reports  (5/7/21)
COVID-19 brought record-setting investment to the healthcare industry in 2020, but this year is shaping up to be even better, reports McAlinden Research Partners. Demand for telehealth services skyrocketed during the pandemic, and funding is starting to follow suit.

More >

Virtual Care Solutions Company Adds New Clients, Expands Care Management Team
Source: Streetwise Reports  (5/7/21)
Reliq Health Technologies reported the addition of four new skilled nursing facility customers in the southern U.S. and announced plans to expand its Care Management Team to meet the growing demand for Care Management Services. More >

Twist Bioscience Shares Wind Higher After Firm Posts 62% YoY Increase in Q2 Revenue
Source: Streetwise Reports  (5/7/21)
Shares of Twist Bioscience Corp. traded 14% higher after the firm reported that orders in Q2/21 grew by 69% year-over-year and that it is raising its FY/21 revenue guidance to $121–129 million. More >

Biotech's Gene Therapy Assets Put It 'Ahead of the Pack'
Source: Streetwise Reports  (5/5/21)
Sio Gene Therapies' focus and strategic portfolio are discussed in an H.C. Wainwright & Co. coverage initiation report. More >

Firm Doubles in Size by Adding Four New Psychedelic Mental Health Clinics
Source: Streetwise Reports  (5/5/21)
Novamind Inc. is opening four new psychedelic mental health clinics as part of the company's national expansion strategy, giving it the capability to conduct 65,000 client visits in 2021. More >

BioNTech Shares Gain 11% on Filing COVID-19 Vaccine Expanded Use Request to EMA in Children Ages 12 to 15
Source: Streetwise Reports  (5/3/21)
BioNTech shares established a new 52-week high price after the company reported that together with its partner Pfizer it has filed a request to expand Conditional Marketing Authorization of COMIRNATY® in the EU to adolescents ages 12 to 15 for its mRNA-based SARS-CoV-2 vaccine.
More >

CryoLife Shares Trade 18% Higher on Q1 Financial Results
Source: Streetwise Reports  (4/30/21)
Shares of CryoLife Inc. set a new 52-week high intraday price after the company reported that total revenues in Q1/21 increased by 7% YoY to $71.1 million. More >

Galera Posts Positive Data from Phase 1/2 Pancreatic Cancer Trial
Source: Streetwise Reports  (4/29/21)
Galera Therapeutics shares traded 25% higher after the company reported new data from its Phase 1/2 pilot study of dismutase mimetic GC4419 that when used in combination with radiation therapy was shown to nearly double median overall survival time in patients with locally advanced pancreatic cancer. More >